Výsledky vyhledávání - "Swami, Murugappan"

PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Autor: Richard O. Wein, Douglas Adkins, Swami Murugappan, David R. Spigel, Oliver Lee, Danny Rischin, Susanne M. Arnold, Nimit Singhal

Publikováno v: Head & Neck. 38:E1756-E1761

Background Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer (PRISM) trial evaluated the safety and efficacy of panitumumab as second-line monotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0eaf0956ce5922b9b84e7ea1ec6165e3
https://doi.org/10.1002/hed.24311

Zobrazit plný text záznamu

PARTNER: An open-label, randomized, phase 2 study of docetaxel/cisplatin chemotherapy with or without panitumumab as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck

Autor: Shaker Dakhil, Swami Murugappan, Paul H. O'Brien, Jun Dong, Kelly S. Oliner, Rita Axelrod, Gabriela Kornek, Philip R. Debruyne, Shubham Pant, Douglas Adkins, Lori J. Wirth

Publikováno v: Oral oncology. 61

This phase 2 estimation study evaluated docetaxel/cisplatin with/without panitumumab, an anti-epidermal growth factor receptor monoclonal antibody, as first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN).Ra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c6e8f4cb9affc1dc62131648b12493
https://pubmed.ncbi.nlm.nih.gov/27688102

Zobrazit plný text záznamu

Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy

Autor: F. Stephen Hodi, Zsolt Szabo, Howard L. Kaufman, J. Randolph Hecht, Igor Puzanov, Kevin J. Harrington, Swami Murugappan

Publikováno v: Expert review of anticancer therapy. 15(12)

Tumor immunotherapy is emerging as a promising new treatment option for patients with cancer. T-VEC is an intralesional oncolytic virus therapy based on a modified herpes simplex virus type-1. T-VEC selectively targets tumor cells, causing regression

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c62f4e06564874033bb5d1636eae460
https://pubmed.ncbi.nlm.nih.gov/26558498

Zobrazit plný text záznamu

PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

Autor: Danny, Rischin, David R, Spigel, Douglas, Adkins, Richard, Wein, Susanne, Arnold, Nimit, Singhal, Oliver, Lee, Swami, Murugappan

Publikováno v: Headneck. 38

Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer (PRISM) trial evaluated the safety and efficacy of panitumumab as second-line monotherapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d83056762cd613527ad77bc0a486492b
https://pubmed.ncbi.nlm.nih.gov/26681429

Zobrazit plný text záznamu